|
May 16
|
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
|
|
May 16
|
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
|
|
May 15
|
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
May 15
|
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
|
|
May 15
|
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 15
|
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
May 14
|
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
|
|
May 13
|
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
May 13
|
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 10
|
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
|
|
May 7
|
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
|
|
May 2
|
Mustang Bio Announces Closing of $4 Million Public Offering
|
|
May 1
|
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
|
|
Apr 30
|
Mustang Bio Announces Pricing of $4 Million Public Offering
|
|
Apr 29
|
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
|
|
Apr 25
|
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
|
|
Apr 24
|
Avenue Therapeutics Announces Reverse Stock Split
|
|
Mar 28
|
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 28
|
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
|
Mar 25
|
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
|